These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 15245864)

  • 1. In vitro activity of protegrin-1 and beta-defensin-1, alone and in combination with isoniazid, against Mycobacterium tuberculosis.
    Fattorini L; Gennaro R; Zanetti M; Tan D; Brunori L; Giannoni F; Pardini M; Orefici G
    Peptides; 2004 Jul; 25(7):1075-7. PubMed ID: 15245864
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activity of human beta defensin-1 and its motif against active and dormant Mycobacterium tuberculosis.
    Sharma R; Saikia UN; Sharma S; Verma I
    Appl Microbiol Biotechnol; 2017 Oct; 101(19):7239-7248. PubMed ID: 28856417
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Comparison of the proteomes of isoniazid-resistant Mycobacterium tuberculosis strains and isoniazid-susceptible strains].
    Jiang X; Gao F; Zhang WH; Hu ZY; Wang HH
    Zhonghua Jie He He Hu Xi Za Zhi; 2007 Jun; 30(6):427-31. PubMed ID: 17673015
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Determination of in vitro synergy when three antimicrobial agents are combined against Mycobacterium tuberculosis.
    Bhusal Y; Shiohira CM; Yamane N
    Int J Antimicrob Agents; 2005 Oct; 26(4):292-7. PubMed ID: 16150578
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral streptococci exhibit diverse susceptibility to human beta-defensin-2: antimicrobial effects of hBD-2 on oral streptococci.
    Nishimura E; Eto A; Kato M; Hashizume S; Imai S; Nisizawa T; Hanada N
    Curr Microbiol; 2004 Feb; 48(2):85-7. PubMed ID: 15057473
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Isoniazid's bactericidal activity ceases because of the emergence of resistance, not depletion of Mycobacterium tuberculosis in the log phase of growth.
    Gumbo T; Louie A; Liu W; Ambrose PG; Bhavnani SM; Brown D; Drusano GL
    J Infect Dis; 2007 Jan; 195(2):194-201. PubMed ID: 17191164
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of human neutrophil peptide-1 as a possible adjunct to antituberculosis chemotherapy.
    Kalita A; Verma I; Khuller GK
    J Infect Dis; 2004 Oct; 190(8):1476-80. PubMed ID: 15378441
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antimicrobial activity and structure of a consensus human β-defensin and its comparison to a novel putative hBD10.
    Rodriguez A; Pedersen MØ; Villegas E; Rivas-Santiago B; Villegas-Moreno J; Amero C; Norton RS; Corzo G
    Proteins; 2020 Jan; 88(1):175-186. PubMed ID: 31325337
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Altered expression of isoniazid-regulated genes in drug-treated dormant Mycobacterium tuberculosis.
    Karakousis PC; Williams EP; Bishai WR
    J Antimicrob Chemother; 2008 Feb; 61(2):323-31. PubMed ID: 18156607
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biphasic kill curve of isoniazid reveals the presence of drug-tolerant, not drug-resistant, Mycobacterium tuberculosis in the guinea pig.
    Ahmad Z; Klinkenberg LG; Pinn ML; Fraig MM; Peloquin CA; Bishai WR; Nuermberger EL; Grosset JH; Karakousis PC
    J Infect Dis; 2009 Oct; 200(7):1136-43. PubMed ID: 19686043
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selective effects of nitrofuraldoxime-anti on isoniazid resistant m. tuberculosis.
    Wayne LG; Russell RL
    Scand J Respir Dis; 1966; 47(1):18-26. PubMed ID: 4958046
    [No Abstract]   [Full Text] [Related]  

  • 12. Public health impact of isoniazid-resistant Mycobacterium tuberculosis strains with a mutation at amino-acid position 315 of katG: a decade of experience in The Netherlands.
    van Doorn HR; de Haas PE; Kremer K; Vandenbroucke-Grauls CM; Borgdorff MW; van Soolingen D
    Clin Microbiol Infect; 2006 Aug; 12(8):769-75. PubMed ID: 16842572
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [In-vitro activity of two hybrid synthetic peptides having antimicrobial activity against mycobacteria].
    Zerbini E; Andreu D; Tonarelli G; Sequeira MD
    Rev Argent Microbiol; 2006; 38(4):221-3. PubMed ID: 17370578
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synergistic interactions of SQ109, a new ethylene diamine, with front-line antitubercular drugs in vitro.
    Chen P; Gearhart J; Protopopova M; Einck L; Nacy CA
    J Antimicrob Chemother; 2006 Aug; 58(2):332-7. PubMed ID: 16751637
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro activity of the antimicrobial peptides human and rabbit defensins and porcine leukocyte protegrin against Mycobacterium tuberculosis.
    Miyakawa Y; Ratnakar P; Rao AG; Costello ML; Mathieu-Costello O; Lehrer RI; Catanzaro A
    Infect Immun; 1996 Mar; 64(3):926-32. PubMed ID: 8641802
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and in vitro antimycobacterial activity of 3-substituted 5-hydroxy-5-trifluoro[chloro]methyl-4,5-dihydro-1H-1-(isonicotinoyl) pyrazoles.
    Almeida da Silva PE; Ramos DF; Bonacorso HG; de la Iglesia AI; Oliveira MR; Coelho T; Navarini J; Morbidoni HR; Zanatta N; Martins MA
    Int J Antimicrob Agents; 2008 Aug; 32(2):139-44. PubMed ID: 18571384
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structure-activity relationships in beta-defensin peptides.
    Taylor K; Barran PE; Dorin JR
    Biopolymers; 2008; 90(1):1-7. PubMed ID: 18041067
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel beta-defensin structure: a potential strategy of big defensin for overcoming resistance by Gram-positive bacteria.
    Kouno T; Fujitani N; Mizuguchi M; Osaki T; Nishimura S; Kawabata S; Aizawa T; Demura M; Nitta K; Kawano K
    Biochemistry; 2008 Oct; 47(40):10611-9. PubMed ID: 18785751
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antimycobacterial activity of novel N-(substituted)-2-isonicotinoylhydrazinocarbothioamide endowed with high activity towards isoniazid resistant tuberculosis.
    Sriram D; Yogeeswari P; Yelamanchili Priya D
    Biomed Pharmacother; 2009 Jan; 63(1):36-9. PubMed ID: 18343086
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activity of 7-methyljuglone in combination with antituberculous drugs against Mycobacterium tuberculosis.
    Bapela NB; Lall N; Fourie PB; Franzblau SG; Van Rensburg CE
    Phytomedicine; 2006 Nov; 13(9-10):630-5. PubMed ID: 16987644
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.